PDCD1 and neoplasm: Antibodies that target PD-1 (e.g., nivolumab) or PD-L (atezolizumab) prevent PD-1/PD-L1 interaction, relieving the blockade of the immune response towards tumor cells, with significant clinical benefit to patients [1,2].